Evidence map›Paper›PMID 30970605›Full record

ArticleJournal of clinical medicine2019

GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients.

Maitane Izaguirre, Javier Gómez-Ambrosi, Amaia Rodríguez, Beatriz Ramírez, Sara Becerril, Víctor Valentí, Rafael Moncada, Xabier Unamuno, Camilo Silva, Magdalena de la Higuera and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Observational
  3. Metaflammation in obesity and its therapeutic targeting.Science translational medicine · 2023
    Review
  4. Marine drugs · 2023
    Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maitane IzaguirreMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. mizaguirrea@unav.es.
Javier Gómez-AmbrosiMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. jagomez@unav.es.ORCID 0000-0001-5601-1604
Amaia RodríguezMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. arodmur@unav.es.ORCID 0000-0002-2180-461X
Beatriz RamírezMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. bearamirez@unav.es.
Sara BecerrilMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. sbecmac@unav.es.
Víctor ValentíCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain. vvalenti@unav.es.
Rafael MoncadaCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain. rmoncada@unav.es.
Xabier UnamunoMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. xunamuno@unav.es.
Camilo SilvaCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain. csilvafr@unav.es.
Magdalena de la HigueraDepartment of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona/Madrid, Spain. mhiguera@unav.es.
Javier SalvadorCIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain. jsalvador@unav.es.
Ignacio MonrealDepartment of Biochemistry, Clínica Universidad de Navarra, 31008 Pamplona, Spain. jimonreal@unav.es.
Gema FrühbeckMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. gfruhbeck@unav.es.ORCID 0000-0002-8305-7154
Victoria CatalánMetabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain. vcatalan@unav.es.

Funding

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the ISCIII, Spain. CIBEROBNGobierno de Navarra 10/2018ISCIII-Subdirección General de Evaluación y FEDER (Plan Estatal I + D + I) PI16/01217, PI17/02183 and PI17/02188
6 · The paper itself

Abstract

objectiveGlucagon-like peptide (GLP)-1 has been proposed as a key candidate in glucose improvements after bariatric surgery. Our aim was to explore the role of GLP-1 in surgically-induced type 2 diabetes (T2D) improvement and its capacity to regulate human adipocyte inflammation.

methodsBasal circulating concentrations of GLP-1 as well as during an oral glucose tolerance test (OGTT) were measured in lean and obese volunteers with and without T2D (

resultsWe show that the reduced (

conclusionsOur data indicate that GLP-1 may contribute to glycemic control and exert a role in T2D remission after RYGB. GLP-1 is also involved in limiting inflammation in human visceral adipocytes.

Indexed as

adipose tissuebariatric surgeryGLP-1inflammationobesityT2D remission

Identifiers

PMID30970605
PMCPMC6518381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.